Menopause and treatments

  title={Menopause and treatments},
  author={Virginie Ringa},
  journal={Quality of Life Research},
  • V. Ringa
  • Published 2004
  • Medicine
  • Quality of Life Research
Postmenopausal women comprise close to 10% of the world population. Their quality of life can be affected by menopausal symptoms or diseases associated with the postmenopausal period and by the effects, beneficial or negative, of curative or preventive therapies prescribed for these disorders. Many symptoms have been reported to be associated with menopause, but the question still remains of which are attributable to menopause and which to other causes. Osteoporosis and cardiovascular diseases… 

Hormone Therapy for the Management of Menopausal Symptoms

HT may be a reasonable pharmacotherapy option for the management of menopausal symptoms following complete patient evaluation by experienced clinicians and Updated recommendations addressing management ofMenopausal symptoms, a new HT product containing the spironolactone-analogue drospirenone (DRSP), and discontinuation methods of HT are discussed.

Novel Lipid Indices as a Better Marker of Cardiovascular Disease Risk in Postmenopausal Women

This study has been undertaken on the role of various lipid indices like Atherogenic Index of Plasma (AIP), Castelli Risk Index I and II, non-HDL cholesterol (NHDL-C), and atherogenic coefficient (AC) in assessing the risk of CVD in postmenopausal women with the following objectives.

Anxiety in Natural and Surgical Menopause — Physiologic and Therapeutic Bases

The participation of ovarian hormones in the regulation of emotional and affective disorders in women with natural or surgical menopause is reviewed; particularly their anatomical pathways, neurotransmission systems, and the resulting behavioural patterns.

Symptoms during Menopausal Transition: Age at Onset, Prevalence and Burden among Women in Delta State, Nigeria

It was concluded that most symptoms were reported by women of post menopausal age, and Vasomotor and sexual domains symptoms were frequently complained of in comparism with the physical and psychosocial domains, though the women did not find the experiences bothersome.

Examining the Relationship between Inflammatory Markers and Menopausal Status in Breast Cancer Patients Undergoing Chemotherapy Treatment

  • N. Ma
  • Medicine, Biology
  • 2011
It is indicated that menopausal status does not account for the variability observed in inflammatory biomarker data in women with breast cancer prior to or following chemotherapy.

Exercise in Menopausal Women

Data suggests that women who participate in regular exercise experience less menopausal symptoms than those who do not; therefore exercise may present a safe and accessible therapy for the symptoms of menopause, and the need for more well-designed, appropriately powered studies in the future is highlighted.

Menopause: A Contextualized Experience Across Social Structures

This chapter applies three theoretical frameworks to the menopausal experience, depicting menopause as a lifelong process that is shaped by the current time period with early life advantages or disadvantages that affect women as they enter their menopausal years.

The Study of Plasma Homocysteine and Lipid Profile Levels as Markers of Cardiovascular Disease in Pre and Postmenopausal Women

There is a significant increase in homocysteine levels than lipid profile parameters, hence homocy steine may be consider as a sensitive marker of CVD’s in postmenopausal women.

Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan

Not only patients ≥50 years but also younger patients with tamoxifen treatment had higher risk of subsequent endometrial cancer in this nation-wide cohort and regular gynecologic monitoring is suggested not only during active use but also during follow-up phase.

To exercise, or, not to exercise, during menopause and beyond.



Hormone replacement therapy: the perspectives for the 21st century.

Hormone replacement therapy

Routine oestrogen treatment should not be recommended until more risk:benefit data are available from clinical trials, based on observations during 25 years of research into women's health, and on Medline searches on oestrogens or menopause.

The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.

Compliance with hormone therapy.

  • V. Ravnikar
  • Medicine
    American journal of obstetrics and gynecology
  • 1987

Menopause and risk of cardiovascular disease: the Framingham study.

Although cholesterol and hemoglobin did rise somewhat more steeply in women undergoing the menopause, this greater incidence of cardiovascular disease in postmenopausal women could not be explained by the influence of theMenopause on the usual cardiovascular risk factors.

An Assessment of Hormone Replacement Therapy to Prevent Postmenopausal Osteoporosis

  • M. Dören
  • Medicine, Biology
    Osteoporosis International
  • 1999
Evidence indicates that the postmenopausal decline in estradiol synthesis may be responsible not only for the more rapid bone loss in early menopause but also for the slower phase of bone loss at older age, suggesting strategies to reduce the incidence of low bone mass and subsequent fragility fractures are of pivotal importance.

Treatment of osteoporosis in elderly women.

  • J. Kanis
  • Medicine
    The American journal of medicine
  • 1995
It is suggested that greater attention should be given to the management of osteoporosis in the elderly and that the optimum age for starting treatment might be best directed 15 or so years after the menopause, well before the mean age of hip fracture.